Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.

Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure

CALCAGNO, Andrea
First
;
PAGANI, NICOLE;ARIAUDO, ALESSANDRA;CARCIERI, CHIARA;D'AVOLIO, ANTONIO;MARINARO, Letizia;TRENTINI, Laura;DI PERRI, Giovanni;BONORA, Stefano
Last
2017

Abstract

Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.
72
6
1741
1744
Calcagno, A; Pagani, N; Ariaudo, A; Arduino, G; Carcieri, C; D'Avolio, A; Marinaro, L; Tettoni, M C; Trentini, L; Di Perri, G; Bonora, S
File in questo prodotto:
File Dimensione Formato  
dkx052.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 118.1 kB
Formato Adobe PDF
118.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1645389
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 10
social impact